BML-11, A lipoxin receptor agonist, protected carbon tetrachloride-induced hepatic fibrosis in rats

Inflammation

Volumn 36, Issue 5, 2013, Pages 1101-1106

  Zhou, Xiao Yan ^a   Yu, Zhong Jian ^a   Yan, Dan ^a   Wang, Hong Mei ^a   Huang, Yong Hong ^a   Sha, Juan ^a   Xu, Fang Yun ^a   Cai, Zhen Yu ^a   Min, Wei Ping ^a,b  

^a NANCHANG UNIVERSITY   (China)

^b Jiangxi Institute of Medical Science   (China)

Author keywords

carbon tetrachloride; inflammation; Lipoxin; liver fibrosis

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; ANTIINFLAMMATORY AGENT; BML 11; COLLAGEN; LIPOXIN RECEPTOR; PLATELET DERIVED GROWTH FACTOR; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; DOWN REGULATION; ENZYME LINKED IMMUNOSORBENT ASSAY; HISTOPATHOLOGY; LIVER FIBROSIS; LIVER NECROSIS; LIVER PROTECTION; NONHUMAN; PROTEIN EXPRESSION; RAT; WESTERN BLOTTING;

RATTUS;

ACTINS; ANIMALS; CARBON TETRACHLORIDE; COLLAGEN; DOWN-REGULATION; GENE EXPRESSION; HEPTANOIC ACIDS; INFLAMMATION; LIVER; LIVER CIRRHOSIS; PLATELET-DERIVED GROWTH FACTOR; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, LIPOXIN; TRANSFORMING GROWTH FACTOR BETA1;

EID: 84885190612     PISSN: 03603997     EISSN: 15732576     Source Type: Journal    
DOI: 10.1007/s10753-013-9643-x     Document Type: Article

References (32)

1. Serhan, C.N. 2002. Lipoxin and aspirin-triggered 15-epi-lipoxin biosynthesis: an update and role in anti-inflammation and pro-resolution. Prostaglandins & Other Lipid Mediators 68-69: 433-455.
2. Fiorucci, S., J.L. Wallace, A. Mencarelli, et al. 2004. A beta-oxidation-resistant lipoxin A4 analog treats hapten-induced colitis by attenuating inflammation and immune dysfunction. Proceedings of the National Academy of Sciences of the United States of America 101: 15736-15741.
3. McMahon, B., S. Mitchell, H.R. Brady, et al. 2001. Lipoxins: revelations on resolution. Trends in Pharmacological Sciences 22: 391-395.
4. O'Meara, Y.M., and H.R. Brady. 1997. Lipoxins, leukocyte recruitment and the resolution phase of acute glomerulonephritis. Kidney International. Supplement 58: S56-S61.
5. Diamond, P., A. McGinty, D. Sugrue, et al. 1999. Regulation of leukocyte trafficking by lipoxins. Clinical Chemistry and Laboratory Medicine 37(3): 293-297.
6. Machado, F.S., J.E. Johndrow, L. Esper, et al. 2006. Anti-inflammatory actions of lipoxin A4 and aspirin-triggered lipoxin are SOCS-2 dependent. Nature Medicine 12: 330-334.
7. Chiang, N., M. Arita, and C.N. Serhan. 2005. Anti-inflammatory circuitry: lipoxin, aspirin-triggered lipoxins and their receptor ALX. Prostaglandins, Leukotrienes, and Essential Fatty Acids 73: 163-177.
8. Mitchell, S., G. Thomas, K. Harvey, et al. 2002. Lipoxins, aspirin-triggered epi-lipoxins, lipoxin stable analogues, and the resolution of inflammation: stimulation of macrophage phagocytosis of apoptotic neutrophils in vivo. Journal of the American Society of Nephrology 13: 2497-2507.
9. Serhan, C.N., J.F. Maddox, N.A. Petasis, et al. 1995. Design of lipoxin A4 stable analogs that block transmigration and adhesion of human neutrophils. Biochemistry 34(44): 14609-14615.
10. Lee, T.H., P. Lympany, and A.E. Crea. 1991. Inhibition of leukotriene B4-induced neutrophil migration by lipoxin A4: structure-function relationships. Biochemical and Biophysical Research Communications 180(3): 1416-1421.
11. Zhang, L., J. Wan, H. Li, et al. 2007. Protective effects of BML-111, a lipoxin A(4) receptor agonist, on carbon tetrachloride-induced liver injury in mice. Hepatology Research 37(11): 948-956.
12. Gong, J., S. Guo, H.B. Li, et al. 2012. BML-111, a lipoxin receptor agonist, protects haemorrhagic shock-induced acute lung injury in rats. Resuscitation 83(7): 907-912.
13. Wang Q, Li R, Ying BY, et al. 2013 Mar 7. Lipoxin A4 activates alveolar epithelial ENaC, Na, K-ATPase and increases alveolar fluid clearance. American Journal of Respiratory Cell and Molecular Biology.
14. Lin, F., P. Zeng, Z. Xu, et al. 2012. Treatment of Lipoxin A(4) and its analogue on low-dose endotoxin induced preeclampsia in rat and possible mechanisms. Reproductive Toxicology 34(4): 677-685.
15. Pei, L., J. Zhang, F. Zhao, et al. 2011. Annexin 1 exerts anti-nociceptive effects after peripheral inflammatory pain through formyl-peptide-receptor-like 1 in rat dorsal root ganglion. British Journal of Anaesthesia 107(6): 948-958.
16. Conte, F.P., O. Menezes-de-Lima Jr., W.A. Verri Jr., et al. 2010. Lipoxin A(4) attenuates zymosan-induced arthritis by modulating endothelin-1 and its effects. British Journal of Pharmacology 161(4): 911-924.
17. Zhang, L., X. Zhang, P. Wu, et al. 2008. BML-111, a lipoxin receptor agonist, modulates the immune response and reduces the severity of collagen-induced arthritis. Inflammation Research 57(4): 157-162.
18. Zhou, X.Y., Y.S. Li, P. Wu, et al. 2009. Lipoxin A4 inhibited hepatocyte growth factor-induced invasion of human hepatoma cells. Hepatology Research 39: 921-930.
19. Hao, H., M. Liu, P. Wu, et al. 2011. Lipoxin A4 and its analog suppress hepatocellular carcinoma via remodeling tumor microenvironment. Cancer Letters 309: 85-94.
20. Chen, Y., H. Hao, S. He, et al. 2010. Lipoxin A4 and its analogue suppress the tumor growth of transplanted H22 in mice: the role of antiangiogenesis. Molecular Cancer Therapeutics 9: 2164-2174.
21. Iredale, J.P. 2007. Models of liver fibrosis: exploring the dynamic nature of inflammation and repair in a solid organ. The Journal of Clinical Investigation 117: 539-548.
22. Kodama, T., T. Takehara, H. Hikita, et al. 2011. Increases in p53 expression induce CTGF synthesis by mouse and human hepatocytes and result in liver fibrosis in mice. The Journal of Clinical Investigation 121: 3343-3356.
23. Gressner, A.M., and R. Weiskirchen. 2006. Modern pathogenetic concepts of liver fibrosis suggest stellate cells and TGF-beta as major players and therapeutic targets. Journal of Cellular and Molecular Medicine 10: 76-99.
24. Hernandez-Gea, V., and S.L. Friedman. 2011. Pathogenesis of liver fibrosis. Annual Review of Pathology 6: 425-456.
25. Friedman, S.L. 2008. Hepatic fibrosis - overview. Toxicology 254: 120-129.
26. Nissen, N.N., and P. Martin. 2002. Hepatocellular carcinoma: the high-risk patient. Journal of Clinical Gastroenterology 35: S79-S85.
27. Bataller, R., and D.A. Brenner. 2005. Liver fibrosis. The Journal of Clinical Investigation 115: 209-218.
28. Friedman, S.L. 2010. Evolving challenges in hepatic fibrosis. Nature Reviews. Gastroenterology & Hepatology 7: 425-436.
29. Friedman, S.L. 2008. Mechanisms of hepatic fibrogenesis. Gastroenterology 134: 1655-1669.
30. Leask, A., and D.J. Abraham. 2004. TGF-beta signaling and the fibrotic response. The FASEB Journal 18: 816-827.
31. Börgeson, E., N.G. Docherty, M. Murphy, et al. 2011. Lipoxin A4 and benzo-lipoxin A4 attenuate experimental renal fibrosis. The FASEB Journal 25: 2967-2979.
32. Lawrence, T., and D.W. Gilroy. 2007. Chronic inflammation: a failure of resolution? International Journal of Experimental Pathology 88(2): 85-94.